Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Announces Sale of Three MassArray Systems

NEW YORK, April 4 – Sequenom said Wednesday it has sold three MassArray Systems, bringing the company’s installed base to 29 sites worldwide.

Sequenom of San Diego said the announcement includes the sale of a second system to the Whitehead Institute’s Center for Genome Research and initial sales to Galileo Genomics, a population genetics company based in Montreal, and to an undisclosed customer.

Sequenom did not say how much the systems sold for, but in the past the company has said that the price of the MassArray is between $400,000 and $1.1 million depending on consumables. 

The news follows on the heals of an announcement last week in which Sequenom of San Diego said it completed the sale of four systems, including sales to customers in Europe and Korea.

The MassArray system, first commercialized in early 2000, provides a platform for genotyping experiments without the use of fluorescence or other tagging techniques. Instead, the company's technology applies MALDI-TOF mass spectrometry directly to fragments of DNA to detect SNPs.  

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.